Tafinlar (Dabrafenib) 75mg Capsules | BRAF Inhibitor | Novartis Switzerland | GLT

Switzerland is the home country of Novartis, and this Tafinlar is the originator dabrafenib product supplied from the Swiss market in 75 mg capsules. For patients and institutions that prefer originator-brand medicines from a European Union-adjacent, Swissmedic-regulated market, this presentation offers that assurance.

Generic Information: Tafinlar (Switzerland)

Tafinlar is Novartis's branded dabrafenib, a targeted therapy for cancers that depend on a mutated BRAF gene. The Swiss 75 mg capsule is identical in active ingredient and formulation to Tafinlar sold elsewhere, differing mainly in packaging and the market it is distributed in.

What Is Tafinlar (Dabrafenib) Used For?

This medicine is used when a tumor tests positive for a BRAF V600 mutation. The main indications are unresectable or metastatic melanoma, adjuvant treatment of melanoma after surgery (with trametinib), and — always with trametinib — BRAF V600E-mutated metastatic non-small cell lung cancer and anaplastic thyroid cancer.

How Does Tafinlar Work?

In normal cells the BRAF protein relays growth signals in a tightly controlled way. In BRAF-mutant cancers the protein is stuck in the "on" position. Dabrafenib selectively binds the mutated form and silences it, cutting the growth signal that the cancer depends on. Adding trametinib blocks a second point in the same pathway for a stronger, longer-lasting effect.

Indications

• BRAF V600E/K-mutant unresectable or metastatic melanoma
• Adjuvant melanoma treatment with trametinib
• BRAF V600E metastatic NSCLC with trametinib
• BRAF V600E anaplastic thyroid cancer with trametinib

Dosage & Administration

The usual dose is 150 mg twice daily, taken as two 75 mg capsules each time, with or without food. Capsules should be swallowed whole with water. Dosing may be interrupted or reduced under medical supervision if side effects occur.

Side Effects

Fever is the most characteristic side effect and needs prompt attention. Other common reactions include tiredness, rash, nausea, headache, chills and joint pain. Serious but less common risks are new skin cancers, bleeding, heart problems, eye inflammation and elevated blood sugar, all of which call for regular monitoring during therapy.

Storage & Handling

Keep at room temperature in the original packaging, away from moisture and light, and out of children's reach. Do not use past the printed expiry date.

Why Choose the GLT?

• Swiss-sourced originator — Tafinlar from the Novartis home market.
• Authentic with documentation — batch records support traceability.
• Worldwide shipping — GLT delivers to institutions and patients globally.

How to Order Tafinlar (Switzerland) from GLT

1. Reach GLT at WhatsApp +86 15234153837 or email [email protected] with quantity and destination.
2. Receive a quotation and estimated delivery time.
3. Complete payment via Hao Yi Lian / 好易联.
4. Goods ship with batch documentation and tracking.

A valid prescription may be requested before dispatch. Both institutions and individual patients are served.

FAQ

1. Is this the same Tafinlar sold in the US or EU?

It contains the same dabrafenib active ingredient and formulation; it is the originator product supplied from the Swiss market.

2. What strength is available?

This listing covers the 75 mg capsule.

3. Is a prescription needed?

Yes, dabrafenib is prescription-only, and a prescription may be requested before dispatch.